Nevro Corp (NVRO) Receives $99.71 Average PT from Analysts

Nevro Corp (NYSE:NVRO) has earned a consensus rating of “Hold” from the eleven ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $99.71.

A number of analysts have recently issued reports on NVRO shares. Zacks Investment Research raised shares of Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. BidaskClub downgraded shares of Nevro from a “sell” rating to a “strong sell” rating in a report on Tuesday, November 14th. Canaccord Genuity dropped their price target on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Northland Securities reaffirmed a “buy” rating and set a $96.00 price target on shares of Nevro in a report on Tuesday, November 7th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $110.00 price target (up previously from $105.00) on shares of Nevro in a report on Tuesday, November 7th.

Several institutional investors and hedge funds have recently bought and sold shares of NVRO. Prudential Financial Inc. boosted its stake in shares of Nevro by 13.8% during the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock valued at $214,000 after purchasing an additional 350 shares during the period. BlackRock Inc. increased its position in Nevro by 13.5% in the 2nd quarter. BlackRock Inc. now owns 1,787,896 shares of the medical equipment provider’s stock valued at $133,073,000 after acquiring an additional 212,656 shares during the period. PNC Financial Services Group Inc. acquired a new stake in Nevro in the 2nd quarter valued at approximately $190,000. UBS Asset Management Americas Inc. increased its position in Nevro by 13.5% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 12,930 shares of the medical equipment provider’s stock valued at $962,000 after acquiring an additional 1,533 shares during the period. Finally, Northern Trust Corp increased its position in Nevro by 14.7% in the 2nd quarter. Northern Trust Corp now owns 324,930 shares of the medical equipment provider’s stock valued at $24,185,000 after acquiring an additional 41,647 shares during the period.

Nevro (NYSE:NVRO) traded up $0.30 during trading hours on Tuesday, reaching $80.10. 247,428 shares of the company’s stock were exchanged, compared to its average volume of 316,229. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81. Nevro has a 1-year low of $65.00 and a 1-year high of $99.63.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://ledgergazette.com/2018/02/18/nevro-corp-nvro-receives-99-71-average-pt-from-analysts.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply